Clinical Trial Update: Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects [Phase 2]

View source ↗

Summary

Phase 2 study of ABT-267 in adults with chronic hepatitis C infection completed; safety, tolerability, pharmacokinetics, and antiviral activity results were pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ABT-267

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Chronic Hepatitis C Infection | Phase 2 | Status: COMPLETED | Results posted: 2015-01-08